Center-Authored Papers

Filters: Author is McGowan, Ian  [Clear All Filters]
2017
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2017.  Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.. Annals of internal medicine. :1-10. Abstract
Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu C-S, Marzinke MA, Hendrix CW, Piper JM, Richardson BA et al..  2017.  High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.. PloS one. 12(7):e0181607. Abstract
2016
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2016.  PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).. The Journal of infectious diseases. Abstract
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Kiweewa FM, Nair G, Mhlanga F et al..  2016.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.. The New England journal of medicine. Abstract
Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu C-S, Galaska B, Jacobson CE et al..  2016.  MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
2015
Madan RP, Dezzutti CS, Rabe L, Hillier SL, Marrazzo J, McGowan I, Richardson BA, Herold BC.  2015.  Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.. American journal of reproductive immunology (New York, N.Y. : 1989). Abstract
McGowan I, Anton PA, Elliott J, Cranston RD, Duffill K, Althouse AD, Hawkins KL, De Rosa SC.  2015.  Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials.. PloS one. 10(5):e0126454. Abstract
Hladik F, Burgener A, Ballweber L, Gottardo R, Vojtech L, Fourati S, Dai JY, Cameron MJ, Strobl J, Hughes SM et al..  2015.  Mucosal effects of tenofovir 1% gel.. eLife. 4 Abstract
2013
McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, Carballo-Dieguez A, Ayudhya RKN, Piper J, Hladik F et al..  2013.  A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).. PloS one. 8(4):e60147. Abstract
2011
McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C.  2011.  Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).. AIDS (London, England). 25(8):1057-64. Abstract